PT Darya-Varia Laboratoria Tbk

IDX:DVLA Rapporto sulle azioni

Cap. di mercato: Rp1.8t

Darya-Varia Laboratoria Performance dei guadagni passati

Il passato criteri di controllo 4/6

Darya-Varia Laboratoria's earnings have been declining at an average annual rate of -11.6%, while the Pharmaceuticals industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 1.4% per year. Darya-Varia Laboratoria's return on equity is 13.1%, and it has net margins of 9.1%.

Informazioni chiave

-11.6%

Tasso di crescita degli utili

-11.7%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore20.4%
Tasso di crescita dei ricavi1.4%
Rendimento del capitale proprio13.1%
Margine netto9.1%
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come Darya-Varia Laboratoria guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

IDX:DVLA Ricavi, spese e utili (IDR Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 242,134,031193,905861,6830
30 Jun 241,995,668169,381820,8500
31 Mar 241,910,016152,911804,3510
31 Dec 231,890,888146,336797,5160
30 Sep 231,739,18983,901800,9340
30 Jun 231,815,69376,354848,5850
31 Mar 231,783,94873,275838,0270
31 Dec 221,917,041149,375830,4270
30 Sep 221,856,94543,735902,0830
30 Jun 222,009,621182,520836,6090
31 Mar 222,058,892202,596822,5500
31 Dec 211,900,894146,505806,0710
30 Sep 212,120,581282,843760,2330
30 Jun 211,876,676156,427749,7780
31 Mar 211,834,423186,516703,3530
31 Dec 201,829,700162,073726,5480
30 Sep 201,680,412191,500640,3920
30 Jun 201,827,255246,976656,6090
31 Mar 201,814,913195,056704,9920
31 Dec 191,813,020221,783678,0040
30 Sep 191,875,188214,986725,2810
30 Jun 191,799,139206,116699,0690
31 Mar 191,750,915221,007659,4710
31 Dec 181,699,657200,652675,3360
30 Sep 181,598,083153,113686,4450
30 Jun 181,597,357149,482693,7980
31 Mar 181,607,717141,526717,5290
31 Dec 171,575,647162,249681,3390
30 Sep 171,515,073187,072636,3470
30 Jun 171,479,646189,754614,1370
31 Mar 171,470,354179,081603,7250
31 Dec 161,451,357152,083596,5070
30 Sep 161,472,526147,533595,3550
30 Jun 161,399,810113,992599,2840
31 Mar 161,343,054104,633580,1920
31 Dec 151,306,098107,894558,1350
30 Sep 151,269,185101,501534,5690
30 Jun 151,290,566108,668526,5460
31 Mar 151,228,853158,858465,1390
31 Dec 141,103,82281,598486,3450
30 Sep 141,073,326108,552451,6400
30 Jun 14985,45397,391449,8950
31 Mar 141,032,13764,584523,4050
31 Dec 131,101,684125,796511,7480

Guadagni di qualità: DVLA has high quality earnings.

Margine di profitto in crescita: DVLA's current net profit margins (9.1%) are higher than last year (4.8%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: DVLA's earnings have declined by 11.6% per year over the past 5 years.

Accelerare la crescita: DVLA's earnings growth over the past year (131.1%) exceeds its 5-year average (-11.6% per year).

Guadagni vs Settore: DVLA earnings growth over the past year (131.1%) exceeded the Pharmaceuticals industry 4%.

Rendimento del capitale proprio

ROE elevato: DVLA's Return on Equity (13.1%) is considered low.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y